Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations

Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of surgical oncology 2000-03, Vol.7 (2), p.155-159
Hauptverfasser: Issakov, J, Merimsky, O, Gutman, M, Kollender, Y, Lev-Chelouche, D, Abu-Abid, S, Lifschitz-Mercer, B, Inbar, M, Klausner, J M, Meller, I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 159
container_issue 2
container_start_page 155
container_title Annals of surgical oncology
container_volume 7
creator Issakov, J
Merimsky, O
Gutman, M
Kollender, Y
Lev-Chelouche, D
Abu-Abid, S
Lifschitz-Mercer, B
Inbar, M
Klausner, J M
Meller, I
description Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients. Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels. The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%-90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (>90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size. This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.
doi_str_mv 10.1007/s10434-000-0155-1
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2415584218</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2415584218</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-fd153d4bb18ea1c7f482d711cefd25a88b5f4732aea8170e38734f4b72ae40aa3</originalsourceid><addsrcrecordid>eNo1UMtKxTAUDKL4_gA3EnAdTdq0ie5EfIHgRteX0zxsLm1Tc1Ll_ojfa0RdnWHOMMMMISeCnwvO1QUKLmvJOOeMi6ZhYovsi6YwstViu2DeanZZtc0eOUBccy5UzZtdsie4aoW6bPfJ18Nmdin3Lo3B0IBxgOwsHcLY0fLwC4Y40c-Qe5qXMSY6OZMiBqQeTI6JwTD3QGGydHQ_cICJhomC_YDJFCeMPrMcEBdHEZKJI-AV7QPmOEPu4xDfgoGBmjhhsC5BLoF4RHY8DOiO_-4heb27fbl5YE_P9483109sruomM29LXSu7TmgHwigvdWWVEMZ5WzWgddd4qeoKHGihuKu1qqWXnSqM5AD1ITn79Z1TfF8c5tU6LmkqkatKlkm1rIQuqtM_1dKNzq7mFEZIm9X_jPU3zoV5cg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2415584218</pqid></control><display><type>article</type><title>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Issakov, J ; Merimsky, O ; Gutman, M ; Kollender, Y ; Lev-Chelouche, D ; Abu-Abid, S ; Lifschitz-Mercer, B ; Inbar, M ; Klausner, J M ; Meller, I</creator><creatorcontrib>Issakov, J ; Merimsky, O ; Gutman, M ; Kollender, Y ; Lev-Chelouche, D ; Abu-Abid, S ; Lifschitz-Mercer, B ; Inbar, M ; Klausner, J M ; Meller, I</creatorcontrib><description>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients. Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels. The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%-90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (&gt;90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size. This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/s10434-000-0155-1</identifier><identifier>PMID: 10761796</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic Agents, Alkylating - administration &amp; dosage ; Blood vessels ; Chemotherapy ; Chemotherapy, Cancer, Regional Perfusion ; Extremities ; Female ; Fibrosis ; Hemorrhage ; Histiocytoma ; Humans ; Hyperthermia, Induced ; Liposarcoma ; Lymph nodes ; Male ; Melphalan ; Melphalan - administration &amp; dosage ; Middle Aged ; Muscles ; Necrosis ; Nerves ; Perfusion ; Radiation therapy ; Sarcoma ; Sarcoma - pathology ; Soft Tissue Neoplasms - pathology ; Soft tissues ; Surgery ; Synovial sarcoma ; Thrombosis ; Tumor Necrosis Factor-alpha - administration &amp; dosage ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α ; Tumors</subject><ispartof>Annals of surgical oncology, 2000-03, Vol.7 (2), p.155-159</ispartof><rights>The Society of Surgical Oncology, Inc. 2000.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10761796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Issakov, J</creatorcontrib><creatorcontrib>Merimsky, O</creatorcontrib><creatorcontrib>Gutman, M</creatorcontrib><creatorcontrib>Kollender, Y</creatorcontrib><creatorcontrib>Lev-Chelouche, D</creatorcontrib><creatorcontrib>Abu-Abid, S</creatorcontrib><creatorcontrib>Lifschitz-Mercer, B</creatorcontrib><creatorcontrib>Inbar, M</creatorcontrib><creatorcontrib>Klausner, J M</creatorcontrib><creatorcontrib>Meller, I</creatorcontrib><title>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients. Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels. The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%-90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (&gt;90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size. This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents, Alkylating - administration &amp; dosage</subject><subject>Blood vessels</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Cancer, Regional Perfusion</subject><subject>Extremities</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Hemorrhage</subject><subject>Histiocytoma</subject><subject>Humans</subject><subject>Hyperthermia, Induced</subject><subject>Liposarcoma</subject><subject>Lymph nodes</subject><subject>Male</subject><subject>Melphalan</subject><subject>Melphalan - administration &amp; dosage</subject><subject>Middle Aged</subject><subject>Muscles</subject><subject>Necrosis</subject><subject>Nerves</subject><subject>Perfusion</subject><subject>Radiation therapy</subject><subject>Sarcoma</subject><subject>Sarcoma - pathology</subject><subject>Soft Tissue Neoplasms - pathology</subject><subject>Soft tissues</subject><subject>Surgery</subject><subject>Synovial sarcoma</subject><subject>Thrombosis</subject><subject>Tumor Necrosis Factor-alpha - administration &amp; dosage</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><subject>Tumors</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNo1UMtKxTAUDKL4_gA3EnAdTdq0ie5EfIHgRteX0zxsLm1Tc1Ll_ojfa0RdnWHOMMMMISeCnwvO1QUKLmvJOOeMi6ZhYovsi6YwstViu2DeanZZtc0eOUBccy5UzZtdsie4aoW6bPfJ18Nmdin3Lo3B0IBxgOwsHcLY0fLwC4Y40c-Qe5qXMSY6OZMiBqQeTI6JwTD3QGGydHQ_cICJhomC_YDJFCeMPrMcEBdHEZKJI-AV7QPmOEPu4xDfgoGBmjhhsC5BLoF4RHY8DOiO_-4heb27fbl5YE_P9483109sruomM29LXSu7TmgHwigvdWWVEMZ5WzWgddd4qeoKHGihuKu1qqWXnSqM5AD1ITn79Z1TfF8c5tU6LmkqkatKlkm1rIQuqtM_1dKNzq7mFEZIm9X_jPU3zoV5cg</recordid><startdate>20000301</startdate><enddate>20000301</enddate><creator>Issakov, J</creator><creator>Merimsky, O</creator><creator>Gutman, M</creator><creator>Kollender, Y</creator><creator>Lev-Chelouche, D</creator><creator>Abu-Abid, S</creator><creator>Lifschitz-Mercer, B</creator><creator>Inbar, M</creator><creator>Klausner, J M</creator><creator>Meller, I</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000301</creationdate><title>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations</title><author>Issakov, J ; Merimsky, O ; Gutman, M ; Kollender, Y ; Lev-Chelouche, D ; Abu-Abid, S ; Lifschitz-Mercer, B ; Inbar, M ; Klausner, J M ; Meller, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-fd153d4bb18ea1c7f482d711cefd25a88b5f4732aea8170e38734f4b72ae40aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents, Alkylating - administration &amp; dosage</topic><topic>Blood vessels</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Cancer, Regional Perfusion</topic><topic>Extremities</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Hemorrhage</topic><topic>Histiocytoma</topic><topic>Humans</topic><topic>Hyperthermia, Induced</topic><topic>Liposarcoma</topic><topic>Lymph nodes</topic><topic>Male</topic><topic>Melphalan</topic><topic>Melphalan - administration &amp; dosage</topic><topic>Middle Aged</topic><topic>Muscles</topic><topic>Necrosis</topic><topic>Nerves</topic><topic>Perfusion</topic><topic>Radiation therapy</topic><topic>Sarcoma</topic><topic>Sarcoma - pathology</topic><topic>Soft Tissue Neoplasms - pathology</topic><topic>Soft tissues</topic><topic>Surgery</topic><topic>Synovial sarcoma</topic><topic>Thrombosis</topic><topic>Tumor Necrosis Factor-alpha - administration &amp; dosage</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Issakov, J</creatorcontrib><creatorcontrib>Merimsky, O</creatorcontrib><creatorcontrib>Gutman, M</creatorcontrib><creatorcontrib>Kollender, Y</creatorcontrib><creatorcontrib>Lev-Chelouche, D</creatorcontrib><creatorcontrib>Abu-Abid, S</creatorcontrib><creatorcontrib>Lifschitz-Mercer, B</creatorcontrib><creatorcontrib>Inbar, M</creatorcontrib><creatorcontrib>Klausner, J M</creatorcontrib><creatorcontrib>Meller, I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Issakov, J</au><au>Merimsky, O</au><au>Gutman, M</au><au>Kollender, Y</au><au>Lev-Chelouche, D</au><au>Abu-Abid, S</au><au>Lifschitz-Mercer, B</au><au>Inbar, M</au><au>Klausner, J M</au><au>Meller, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2000-03-01</date><risdate>2000</risdate><volume>7</volume><issue>2</issue><spage>155</spage><epage>159</epage><pages>155-159</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients. Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels. The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%-90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (&gt;90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size. This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>10761796</pmid><doi>10.1007/s10434-000-0155-1</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1068-9265
ispartof Annals of surgical oncology, 2000-03, Vol.7 (2), p.155-159
issn 1068-9265
1534-4681
language eng
recordid cdi_proquest_journals_2415584218
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating - administration & dosage
Blood vessels
Chemotherapy
Chemotherapy, Cancer, Regional Perfusion
Extremities
Female
Fibrosis
Hemorrhage
Histiocytoma
Humans
Hyperthermia, Induced
Liposarcoma
Lymph nodes
Male
Melphalan
Melphalan - administration & dosage
Middle Aged
Muscles
Necrosis
Nerves
Perfusion
Radiation therapy
Sarcoma
Sarcoma - pathology
Soft Tissue Neoplasms - pathology
Soft tissues
Surgery
Synovial sarcoma
Thrombosis
Tumor Necrosis Factor-alpha - administration & dosage
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Tumors
title Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A18%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperthermic%20isolated%20limb%20perfusion%20with%20tumor%20necrosis%20factor-alpha%20and%20melphalan%20in%20advanced%20soft-tissue%20sarcomas:%20histopathological%20considerations&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Issakov,%20J&rft.date=2000-03-01&rft.volume=7&rft.issue=2&rft.spage=155&rft.epage=159&rft.pages=155-159&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/s10434-000-0155-1&rft_dat=%3Cproquest_pubme%3E2415584218%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2415584218&rft_id=info:pmid/10761796&rfr_iscdi=true